期刊文献+

滤泡辅助性T细胞在B细胞淋巴瘤免疫微环境中作用的研究进展 被引量:4

Research progress on follicular helper T cell in immune microenviroment of B cell lymphoma
原文传递
导出
摘要 滤泡辅助性T细胞(Tfh)是一种新发现的CD4+T细胞,其对维持机体生发中心活性及体液免疫平衡至关重要。近期多项研究结果表明,Tfh在T细胞淋巴瘤免疫微环境中具有重要作用,而其在B细胞淋巴瘤(BCL)中作用的文献迄今较少。笔者通过对Tfh的分类与功能、BCL的起源及其免疫微环境,以及Tfh与BCL免疫微环境的关系等,对Tfh在BCL免疫微环境中作用的研究进展进行综述。 Follicular helper T cell(Tfh)is a new subset CD4+T cells that is essential for maintaining the activity of germinal center and the balance of humoral immune.Recently,some studies have shown that Tfh played an important role in the immune microenvironment of T cell lymphomas,but there are fewer related studies in B cell lymphoma(BCL).This article reviews the role of Tfh in BCL through the classification and function of Tfh,the origin of BCL and it′s immune microenviroment,and the relationship between Tfh and immune microenviroment of BCL.
作者 郑静 高开波 Zheng Jing;Gao Kaibo(Departments of Hematology,First People′s Hospital of Yichang,China Three Gorges University,Yichang 443000,Hubei Province,China)
出处 《国际输血及血液学杂志》 CAS 2020年第4期362-364,共3页 International Journal of Blood Transfusion and Hematology
基金 湖北省教育厅指导项目(B2019023) 湖北省卫生健康委员会联合基金(WJ2019H506)。
关键词 CD4阳性T淋巴细胞 淋巴瘤 B细胞 T淋巴细胞 辅助诱导 肿瘤微环境 滤泡辅助性T细胞 CD4-positive T-lymphocytes Lymphoma,B-cell T-lymphocytes,helper-inducer Tumor microenvironment Follicular helper T cell
  • 相关文献

参考文献2

二级参考文献43

  • 1肖畅,苏祖兰,吴秋良,郜红艺,方建晨,夏忠军,管忠震.根据WHO新分类对493例非霍奇金淋巴瘤的临床病理分析[J].中华病理学杂志,2005,34(1):22-27. 被引量:54
  • 2程月新,徐卫,李建勇,钱思轩,陆化,吴汉新,陈丽娟.非霍奇金淋巴瘤641例临床分析[J].南京医科大学学报(自然科学版),2006,26(9):837-840. 被引量:15
  • 3周立强,孙燕,谭文勇,李陶,王琦路,冯凤仪,王金万,储大同,石远凯,李晔雄,孙云田,吕宁.非霍奇金淋巴瘤1125例临床病理分析[J].癌症进展,2006,4(5):391-397. 被引量:47
  • 4Vitolo U, Ferreri AJ, Montoto S. Follicular lymphomas. Crit Rev Oncol Hematol, 2008, 66:248-61.
  • 5www.NCCN.com.
  • 6Dreyling M, ESMO Guidelines Working Group. Newly diag- nosed and relapsed follicular lymphoma: ESMO Clinical Prac- tice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2010, 21: v181-3.
  • 7Solal-Coligny P, Roy P, Colombat P, et al. Follicular lymphoma intemational prognostic index. Blood, 2004,104:1258-1265.
  • 8Petersen PM, Gospodarowicz M, Tsang R, et al. Long-term outcome in stage Ⅰ and Ⅱ follicular lymphoma following treatment with involved field radiation therapy alone. J Clin Oncol, 2004, 22(suppl):6521.
  • 9Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low- Grade Lymphoma Study Group. Blood, 2005, 106: 3725-3732.
  • 10Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood, 2005, 105:1417-1423.

共引文献35

同被引文献27

引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部